We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · May 05, 2022

Abiraterone Plus Prednisone Added to ADT and Docetaxel in De Novo Metastatic Castration-Sensitive Prostate Cancer

The Lancet


Additional Info

The Lancet
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design
Lancet 2022 Apr 08;[EPub Ahead of Print], K Fizazi, S Foulon, J Carles, G Roubaud, R McDermott, A Fléchon, B Tombal, S Supiot, D Berthold, P Ronchin, G Kacso, G Gravis, F Calabro, JF Berdah, A Hasbini, M Silva, A Thiery-Vuillemin, I Latorzeff, L Mourey, B Laguerre, S Abadie-Lacourtoisie, E Martin, C El Kouri, A Escande, A Rosello, N Magne, F Schlurmann, F Priou, ME Chand-Fouche, SV Freixa, M Jamaluddin, I Rieger, A Bossi

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Advanced Prostate Cancer Center of Excellence

Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.

Further Reading